BioKaiser Biotech: Revolutionizing Vaccine Adjuvants with Bio-Based Squalene

Squalene is a naturally occurring all-trans triterpene compound containing six double bonds, found in animals, plants, and eukaryotic microorganisms. It is naturally present in human sebum. Squalene exhibits various biological activities, such as antioxidant effects, regulation of cholesterol metabolism, and detoxification, and is widely used in vaccines, health supplements, cosmetics, and food products.

Baikaisheng Biotechnology utilizes its proprietary synthetic biology technology, “organelle compartmentalization” cell factories, complemented by high-density fermentation and advanced extraction processes, to efficiently and specifically synthesize squalene from renewable raw materials. The product complies with European Pharmacopoeia standards (purity ≥98%), offering high production efficiency and infinitely scalable capacity. This technology comprehensively addresses all pain points associated with existing production methods, including shark killing and toxin risks linked to animal-derived extraction, as well as the high costs and pollution associated with plant-based extraction. Baikaisheng Biotechnology has become the world’s first manufacturer of fully biosynthetic, injection-grade squalene and has obtained FDA DMF certification (Reference Number: 038189).

VCBeat Selects New Products Review, Issue 8, featuringWei Jiashi, General Manager of Baikaisheng Biotech,Professor Wang Fengqing, East China University of Science and Technology; Baikaisheng BiologyAssistant to the General Manager and Senior R&D Manager, Zhang BaoqiJoin us for the product launch of Baikaisheng Bio Squalene.

Biosynthesis:Efficient and Specific Synthesis of Squalene via “Organelle Compartmentalization” Cell Factories Based on Synthetic Biology, Safeguarding Biodiversity

Supply Assurance:Renewable biomass as raw material, large-scale production.

High-Standard:Content ≥98%, free from any risk of endotoxins, pyrogens, etc., and complies with the European Pharmacopoeia standards.

Quality Stability:Our proprietary biosynthesis process is unaffected by raw material batch variations, ensuring consistent product quality.

This event has invitedWei Jiashi, General Manager of Baikaisheng Biotech, presented an introduction to the company, while Professor Wang Fengqing from East China University of Science and Technology explained the product.Baikaisheng BiotechZhang Baoqi, Assistant to the General Manager and Senior R&D Manager, presented an overview of the R&D platform.

Welcome to scan the QR code in the poster below to register for the live broadcast:

Wei Jiashi

Baikaisheng Biotech | General Manager

B.S. in Biological Sciences from Fudan University; dual M.S. degrees in Bioengineering and Industrial Engineering from the University of Minnesota, USA. Previously held senior management positions in key process technology, production management, and operations at Agropur Inc., WuXi AppTec (STA Pharmaceuticals), and Promega Corporation. Successfully spearheaded the industrial-scale commercialization of multiple functional ingredients at the thousand-ton level, spanning areas such as biocatalysis and fermentation.

Wang Fengqing

East China University of Science and Technology | Professor, Doctoral Supervisor

Deputy Director of the Key Laboratory of Biocatalysis and Intelligent Manufacturing, China National Light Industry Council. He has long been dedicated to research in metabolic engineering and synthetic biology, with a focus on "microbial synthesis of natural products," "microbial transformation of steroidal drugs," "green biomanufacturing of chemicals," and "engineered probiotics." In recent years, he has successfully achieved the industrialization of multiple projects, including the microbial transformation of steroidal drugs and the microbial synthesis of natural products such as squalene. He has received one First Prize and two Second Prizes for Technological Invention at the provincial and ministerial levels.

Zhang Baoqi

Baikaisheng Biotech | Assistant to the General Manager, Senior R&D Manager

Specializing in enzyme engineering and biocatalysis, with expertise in computer-aided protein design and the application of artificial intelligence to enzyme discovery and engineering, enabling efficient mining and customization of multi-enzyme systems. Has participated in multiple national and provincial/ministerial-level research projects, published numerous SCI-indexed papers, and filed several invention patents. Pioneered the de novo creation of five novel enzymes, and achieved industrial-scale production of two enzyme preparations with applications in the pharmaceutical industry. Achieved the world’s first biosynthetic route to optically pure (R)-citronellal via biocatalysis, thereby establishing a biological manufacturing pathway for L-menthol.

Baikaisheng (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as “Baikaisheng Bio”) was jointly founded by a senior team with over 20 years of dedicated expertise in bioengineering and its industrial applications. Leveraging three mature and leading technological platforms—“Enzymes and Biocatalysis,” “Cell Factories and Biosynthesis,” and “Process Engineering”—the company aims to establish itself as a cutting-edge international platform for green biomanufacturing solutions and product development.

Baikaisheng Biotech is headquartered in the Lingang Nanqiao Science and Technology City (the core area of Fengxian New City) in Shanghai, where it operates a 2,000-square-meter R&D and pilot-scale production base. The company’s portfolio of biocatalysis and biosynthesis pipelines targets the pharmaceutical, health supplement, food, cosmetics, and agricultural sectors. Committed to the large-scale implementation and application of green bio-manufacturing, Baikaisheng has established strategic partnerships with renowned domestic and international pharmaceutical and chemical enterprises.

"Artery Select New Product Launch," a live-streaming program under the "Artery Select" brand, is dedicated to supporting medical enterprises in launching innovative products. The program’s mission is to empower every milestone launch of medical innovations.

Scan the QR code to join the group and register for the live stream

(Already added; please inquire proactively.)